Albus Protocol Received A Grant From Solana Foundation For Development Of Regulation-Compliant DeFi Framework
May 30, 2023. Wollerau, Switzerland – The Solana Foundation provided a grant for research and…
News
Runiverse Announces Official Token Listing on BitMart Exchange
Davos, Switzerland, May 30th – Runiverse, the leading metaverse game, is thrilled to announce the…
Ambrx to Present at Multiple Upcoming Investor Meetings
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) — Ambrx Biopharma Inc., or Ambrx (or the…
Ambrx to Present at Multiple Upcoming Investor Meetings
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) — Ambrx Biopharma Inc., or Ambrx (or the…
T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale in Company History
LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the…
T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale in Company History
LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the…
SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP
As part of the Company’s corporate restructuring plan, Mr. Yaki Baranes will facilitate identifying new…
SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP
As part of the Company’s corporate restructuring plan, Mr. Yaki Baranes will facilitate identifying new…
Aprea Therapeutics to Present at BIO International Convention
DOYLESTOWN, Pa., May 30, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the…
Aprea Therapeutics to Present at BIO International Convention
DOYLESTOWN, Pa., May 30, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the…
Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs
– Company plans to suspend enrollment in the ongoing milademetan Phase 2 MANTRA-2 basket trial…
Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs
– Company plans to suspend enrollment in the ongoing milademetan Phase 2 MANTRA-2 basket trial…
Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs
First subject dosed in Phase 1 trial of PYX-106, a fully human immunotherapy antibody candidate…
Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs
First subject dosed in Phase 1 trial of PYX-106, a fully human immunotherapy antibody candidate…
Cormedix Inc. To Present At The Jefferies Healthcare Conference
BERKELEY HEIGHTS, N.J., May 30, 2023 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical…
Cormedix Inc. To Present At The Jefferies Healthcare Conference
BERKELEY HEIGHTS, N.J., May 30, 2023 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical…
Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy
Results Add to Growing Body of Evidence that Inhibiting PP2A with LB–100 May Be a…
Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy
Results Add to Growing Body of Evidence that Inhibiting PP2A with LB–100 May Be a…
Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
TAMPA, Fla. and MENLO PARK, Calif., May 30, 2023 (GLOBE NEWSWIRE) — Morphogenesis, Inc. (“Morphogenesis”),…
Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
TAMPA, Fla. and MENLO PARK, Calif., May 30, 2023 (GLOBE NEWSWIRE) — Morphogenesis, Inc. (“Morphogenesis”),…